<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645928</url>
  </required_header>
  <id_info>
    <org_study_id>IOV-COM-202</org_study_id>
    <secondary_id>2018-001608-12</secondary_id>
    <nct_id>NCT03645928</nct_id>
  </id_info>
  <brief_title>Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors</brief_title>
  <official_title>A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iovance Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iovance Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating&#xD;
      adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with&#xD;
      checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LN-144 (Lifileucel)/LN-145/LN-145-S1 is an adoptive cell transfer therapy that utilizes an&#xD;
      autologous TIL for the treatment of patients with unresectable or metastatic melanoma,&#xD;
      advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck, and locally&#xD;
      advanced or metastatic non-small cell lung cancer. The adoptive cell transfer therapy used in&#xD;
      this study involves patients receiving a nonmyeloablative (NMA) lymphodepletion regimen,&#xD;
      followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.&#xD;
      Patients in Cohorts 1A, 2A, 3A and 3C will receive TIL plus checkpoint inhibitors. Patients&#xD;
      in Cohorts 1B, 1C, and 3B will receive autologous TIL as a single therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate the efficacy of autologous TIL in combination with CPIs in metastatic melanoma, HNSCC, and NSCLC patients and as a single therapy in metastatic melanoma and NSCLC patients as determined by objective response rate (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by Investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Profile Measured by Grade ≥3 TEAEs</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To characterize the safety profile of autologous TIL in combination with CPIs in metastatic melanoma, HNSCC, and NSCLC patients and as a single therapy in metastatic melanoma and NSCLC patients as measured by the incidence of Grade ≥ 3 treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such Complete Response (CR) rate per RECIST 1.1, as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such Duration of Response (DOR) per RECIST 1.1, as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such Disease Control Rate (DCR) per RECIST 1.1, as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such Progression-Free Survival (PFS) per RECIST 1.1, as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>To evaluate efficacy parameters such Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LN-144 therapy in combination with pembrolizumab in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma with ≤ 3 prior lines of systemic therapy, excluding checkpoint inhibitors (CPI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LN-145-S1 therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor or BRAF inhibitor with or without a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LN-144 Generation 3 (Gen 3) therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LN-145 therapy in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding CPIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LN-145 therapy in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III or Stage IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding CPIs or ≤ 4 prior lines if 2 or more of the lines are TKI therapy for those with tumors that harbored actionable mutations (eg, EGFR, ALK, ROS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LN-145 therapy as a single agent in patients with Stage III or Stage IV NSCLC, who have previously received 1-3 lines of prior systemic therapy. Patients with known oncogene drivers (eg, EGFR, ALK, ROS) who have mutations that are sensitive to targeted therapies are not required to have received prior systemic therapy with CPIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LN-145 therapy in combination with ipilimumab and nivolumab in patients with Stage III or Stage IV NSCLC who have previously received 1 line of approved CPI monotherapy as the only prior line of systemic therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lifileucel</intervention_name>
    <description>A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by IL-2 administration. Lifileucel will be administered to patients once (on Day 0) during the study.</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
    <other_name>LN-144, TIL, autologous tumor infiltrating lymphocytes, lifileucel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LN-145</intervention_name>
    <description>A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.</description>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_label>Cohort 3C</arm_group_label>
    <other_name>TIL, autologous tumor infiltrating lymphocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Humanized antibody.&#xD;
Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years.</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LN-145-S1</intervention_name>
    <description>A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.</description>
    <arm_group_label>Cohort 1B</arm_group_label>
    <other_name>TIL, autologous tumor infiltrating lymphocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Monoclonal antibody&#xD;
Ipilimumab will be administered as a single dose prior to tumor resection.</description>
    <arm_group_label>Cohort 3C</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Monoclonal antibody&#xD;
Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years.</description>
    <arm_group_label>Cohort 3C</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Must have a confirmed diagnosis of malignancy of their receptive histologies:&#xD;
             unresectable or metastatic melanoma Stage IIIC or Stage IV (Cohorts 1A,1B and 1C),&#xD;
             advanced, recurrent or metastatic HNSCC (Cohort 2A), or Stage III or Stage IV&#xD;
             non-small cell lung cancer (Cohorts 3A, 3B, and 3C).&#xD;
&#xD;
          -  Cohorts 1A, 2A, and 3A: If previously treated, patients must have progressed on or&#xD;
             after most recent therapy and must not have received CPIs as part of one of the&#xD;
             counted lines of prior therapy. Patients must have radiologically documented disease&#xD;
             progression while receiving or after the completion of the most recent prior&#xD;
             treatment. Patients may have received up to 3 prior systemic anticancer therapies&#xD;
             (except for Cohort 3A, where patients whose tumors harbor actionable mutations may&#xD;
             have received up to 4 prior systemic therapies)&#xD;
&#xD;
          -  Cohorts 1B, 1C, 3B, and 3C: Unresectable or metastatic melanoma patients in Cohorts 1B&#xD;
             or 1C must have previously received systemic therapy with a PD-1 blocking antibody.&#xD;
             NSCLC patients in Cohort 3B must have previously received systemic therapy with any&#xD;
             CPI (except for those patients with known oncogene drivers (eg, EGFR, ALK, ROS) who&#xD;
             have mutations that are sensitive to targeted therapies) as part of 1 - 3 prior lines&#xD;
             of therapy. NSCLC patients in Cohort 3C must have received prior systemic therapy with&#xD;
             an approved monotherapy CPI as their single prior line of systemic therapy.&#xD;
&#xD;
          -  Must have at least 1 resectable lesion&#xD;
&#xD;
          -  Must have a remaining measurable disease as defined by RECIST 1.1 following tumor&#xD;
             resection&#xD;
&#xD;
          -  Must be ≥ 18 years at the time of consent for Cohorts 1A, 1C, 2A, 3A, 3B, and 3C.&#xD;
             Patients must be ≥ 12 years at the time of consent for Cohort 1B. Enrollment of&#xD;
             patients &gt; 70 years of age may be allowed after consultation with the Medical Monitor.&#xD;
&#xD;
          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,&#xD;
             and an estimated life expectancy of ≥ 6 months.&#xD;
&#xD;
          -  Patients of childbearing potential or those with partners of childbearing potential&#xD;
             must be willing to practice an approved method of birth control during treatment and&#xD;
             for 12 months after receiving all protocol-related therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with melanoma of uveal/ocular origin.&#xD;
&#xD;
          -  Patients who have received an organ allograft or prior cell transfer therapy that&#xD;
             included a nonmyeloablative or myeloablative chemotherapy regimen within the past 20&#xD;
             years.&#xD;
&#xD;
          -  Patients with symptomatic and/or untreated brain metastases&#xD;
&#xD;
          -  Patients who are on systemic steroid therapy ≥ 10 mg/day of prednisone or other&#xD;
             steroid equivalent. Patients receiving steroids as replacement therapy for&#xD;
             adrenocortical insufficiency at ≤ 10 mg/day of prednisone or other steroid equivalent&#xD;
             may be eligible.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Patients who have an active medical illness(es), which in the opinion of the&#xD;
             Investigator, would pose increased risks for study participation&#xD;
&#xD;
          -  Cohort 1A, 2A, 3A, and 3C patients may not have a medical history of autoimmune&#xD;
             disorders (including pneumonitis) requiring treatment or active management.&#xD;
&#xD;
          -  Patients who have received a live or attenuated vaccination within 28 days prior to&#xD;
             the start of treatment&#xD;
&#xD;
          -  Patients who have any form of primary immunodeficiency&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to any component of the study drugs&#xD;
&#xD;
          -  Patients who have a left ventricular ejection fraction (LVEF) &lt; 45% or who are New&#xD;
             York Heart Association Class II or higher&#xD;
&#xD;
          -  Patients with respiratory dysfunction or history of smoking are excluded if not&#xD;
             meeting either of forced expiratory volume in 1 second (FEV1)/forced vital capacity&#xD;
             (FVC) &gt; 0.7 or FEV1 &gt; 50%.&#xD;
&#xD;
          -  Patients who have had another primary malignancy within the previous 3 years&#xD;
&#xD;
          -  Participation in another interventional clinical study within 21 days of the&#xD;
             initiation of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iovance Biotherapeutics Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Iovance Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iovance Biotherapeutics Study Team</last_name>
    <phone>866-565-4410</phone>
    <email>Clinical.Inquiries@iovance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein - Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO l'Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga - Hospital General</name>
      <address>
        <city>Málaga</city>
        <zip>29016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE19RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LN-144</keyword>
  <keyword>LN-145</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Autologous Adoptive Cell Transfer</keyword>
  <keyword>Autologous Adoptive Cell Therapy</keyword>
  <keyword>Cellular Immuno-therapy</keyword>
  <keyword>Tumor Infiltrating Lymphocytes</keyword>
  <keyword>TIL</keyword>
  <keyword>IL-2</keyword>
  <keyword>Multiple Tumor Type</keyword>
  <keyword>Lifileucel</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>LN-145-S1</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>CPI</keyword>
  <keyword>Checkpoint Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

